Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex Plays Defense In CF With Concert Deal

Executive Summary

Vertex is spending $160m to acquire Concert's "enhanced" version of its own blockbuster cystic fibrosis treatment Kalydeco, known as CTP-656, in a defensive move that could allow the company to simplify its dosing regimens and differentiate its products against future competition.

Advertisement

Related Content

Finance Watch: Summer Slowdown Begins Ahead Of BIO, But Two IPOs Launched
Vanda's Licenses CFTR Modulators From UCSF, But Not For Cystic Fibrosis
Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options
Cystic Fibrosis: Successes, Opportunities And Challenges
Cystic Fibrosis: Clinical Assets In Development
Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way
Vertex's VX-661 Has Positive Outlook Despite Futility Finding

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098349

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel